Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (108)

III-001Massimiliano Germani

Model-informed pediatric drug development for clevidipine

Thu, Jun 4, 2026 9:50AM–11:20AM

III-002Núria Folguera Blasco

TEZEPELUMAB POPULATION PHARMACOKINETICS SUPPORTS PAEDIATRIC EXTRAPOLATION IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (CRSwNP)

Thu, Jun 4, 2026 9:50AM–11:20AM

III-003Yannick Hoffert

A population pharmacokinetics and exposure–response framework for tacrolimus dose optimization in intestinal transplantation

Thu, Jun 4, 2026 9:50AM–11:20AM

III-004Anh Thi Van Nguyen

Impact of PK/PD indices on target attainment of vancomycin therapy in critically ill children: back to the drawing board

Thu, Jun 4, 2026 9:50AM–11:20AM

III-005Baralee Punyawudho

Dolutegravir dose optimization based on population pharmacokinetics and pharmacogenetics in Thai people living with HIV

Thu, Jun 4, 2026 9:50AM–11:20AM

III-006Nelleke Snelder

QUANTIFICATION OF INDIVIDUAL Β-CELL FUNCTION AND INSULIN SENSITIVITY: TOWARDS PERSONALISED LIFESTYLE AND MEDICINE TREATMENT

Thu, Jun 4, 2026 9:50AM–11:20AM

III-007Woan Torng Tang

Population Pharmacokinetics/Pharmacodynamics (PK/PD) and Time-to-Event (TTE) Analysis of Major Bleeding for Rivaroxaban-Treated Patients with Atrial Fibrillation: Assessing the Influence of Heart Failure through Left- and Right-Ventricular Performance Markers

Thu, Jun 4, 2026 9:50AM–11:20AM

III-008Wei Zhang

POPULATION PHARMACOKINETICS AND EXPOSURE–RESPONSE MODELING SUPPORTS OPTIMIZED USTEKINUMAB INDUCTION DOSING IN CHRONIC POUCHITIS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-009Martina Chiesa

TOWARD A QUANTITATIVE SYSTEMS PHARMACOLOGY FRAMEWORK OF CELL-LEVEL ALPHA-SYNUCLEIN DYNAMICS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-010Alzahra Hamdan

An Item Response Theory-Based Comparison of Multiple Versions of SARA Rating Assessment of Degenerative Ataxia in a SCA3 Cohort

Thu, Jun 4, 2026 9:50AM–11:20AM

III-011Angelica Quartino

POPULATION PKPD AND EXPOSURE–RESPONSE ANALYSIS OF EPLONTERSEN SUPPORTS 45 MG SC Q4W WITHOUT DOSE ADJUSTMENT IN HEREDITARY TRANSTHYRETIN-MEDIATED POLYNEUROPATHY

Thu, Jun 4, 2026 9:50AM–11:20AM

III-012Malin Andersson

GLOBAL VARIANCE-BASED SENSITIVITY ANALYSIS OF A PHARMACODYNAMIC MODEL FOR PIPERACILLIN/TAZOBACTAM TOWARDS OPTIMISED DOSING STRATEGIES

Thu, Jun 4, 2026 9:50AM–11:20AM

III-013Thomas Bénéteau

ON THE USE OF TECOVIRIMAT FOR MPXV INFECTIONS: WHY DO WE NOT SEE SHORTENED TIMES TO VIRAL CLEARANCE IN TREATED PATIENTS?

Thu, Jun 4, 2026 9:50AM–11:20AM

III-014Jordan Brooks

Model-Informed Precision Dosing of Cefepime: A Simulation Study Evaluating Target Attainment and Neurotoxicity Risk

Thu, Jun 4, 2026 9:50AM–11:20AM

III-015Asina Gijasi

PRECLINICAL-TO-CLINICAL PREDICTIONS OF PHASE 2B CLINICAL TRIAL EFFICACY IN TUBERCULOSIS THROUGH BACK-TRANSLATIONAL MODELING OF RIFAPENTINE-CONTAINING REGIMENS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-016Evangelos Karakitsios

A translational framework for predicting early bactericidal activity of bedaquiline and pretomanid using in vitro time-kill assays

Thu, Jun 4, 2026 9:50AM–11:20AM

III-017Xuanlin Liu

LATE TREATMENT INITIATION LEADS TO REDUCED ANTIVIRAL POTENCY OF NIRMATRELVIR AND GS-441524 AGAINST IN VITRO SARS-COV-2 INFECTION

Thu, Jun 4, 2026 9:50AM–11:20AM

III-018Chen Ma

Host Immunity as a Bidirectional Regulator of Phage Therapy: A Mechanism-Based PKPD Modeling Approach

Thu, Jun 4, 2026 9:50AM–11:20AM

III-019Yersultan Mirasbekov

Population pharmacokinetic modelling of plasma and target-site metronidazole: Reduced target-site exposure suggests underdosing in obese patients

Thu, Jun 4, 2026 9:50AM–11:20AM

III-020Emmanuel Niyigena

Population Pharmacokinetic Modelling of Plasma and Intracellular Bictegravir in People Living with HIV

Thu, Jun 4, 2026 9:50AM–11:20AM

III-021Sharon Sawe

POPULATION PHARMACOKINETICS OF DELAMANID AND ITS MAIN METABOLITE DM-6705 IN BREASTMILK IN PATIENTS TREATED FOR RIFAMPICIN-RESISTANT TUBERCULOSIS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-022Isabella Van Der Feltz

Pharmacokinetic and pharmacodynamics of BTZ-043 in patients with pulmonary tuberculosis

Thu, Jun 4, 2026 9:50AM–11:20AM

III-023Eva Wehrhahn

Time-varying covariates to enhance mechanistic understanding of antibiotic-induced bacterial morphology changes

Thu, Jun 4, 2026 9:50AM–11:20AM

III-024Thijs Jan Zweers

POPULATION PHARMACOKINETICS, ANTIDRUG ANTIBODIES AND EXPOSURE–RESPONSE OF LOTIVIBART (LVB, VH3810109, N6LS) IN VIROLOGICALLY SUPPRESSED ADULTS LIVING WITH HIV FROM THE PHASE 2B EMBRACE STUDY

Thu, Jun 4, 2026 9:50AM–11:20AM

III-025Daniel Bending

Challenges in Extending Semi-Mechanistic Neutropenia Models to Antibody-Drug Conjugate and Chemotherapy Combinations: Implications for G-CSF Dosing Optimisation

Thu, Jun 4, 2026 9:50AM–11:20AM

III-026Daniel Centanni

An Integrated Population Pharmacokinetic Analysis of Peg-Asparaginase Across Multiple Nordic Acute Lymphoblastic Leukemia Treatment Protocols: Characterizing Time-Dependent Clearance Dynamics and Patient Factors Driving Variability

Thu, Jun 4, 2026 9:50AM–11:20AM

III-027

PK/PD modelling and simulations of cambritaxestat-mediated inhibition of autotaxin-lysophosphatidic acid pathway in metastatic pancreatic cancer patients to inform Phase II dose selection

Thu, Jun 4, 2026 9:50AM–11:20AM

III-028Richard Franzese

Joint modeling of tumor size and circulating tumor DNA dynamics to predict overall survival in non-small cell lung cancer

Thu, Jun 4, 2026 9:50AM–11:20AM

III-029Gaston Garcia-Orueta

A semi-mechanistic model describing tumor response to oncolytic virus and anti-PD-1 therapy in preclinical studies

Thu, Jun 4, 2026 9:50AM–11:20AM

III-030Vincent Hurez

USE OF VIRTUAL TWINS TO ESTABLISH A PREDICTIVE MODEL BETWEEN SIMULATED IL-6 CONCENTRATIONS AND CRS RISK DURING ODRONEXTAMAB STEP-UP DOSING IN B-CELL LYMPHOMA PATIENTS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-031Mathilde Marchand

A PREDICTIVE MODELING FRAMEWORK TO RECONSTRUCT AND SIMULATE PFS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-032Anna Mishina

Application of a Simulation-Based Diagnostics for Survival Evaluation in Joint Models

Thu, Jun 4, 2026 9:50AM–11:20AM

III-033Zinnia P Parra-Guillen

A population modelling framework to support early clinical development of BI-1206, a monoclonal antibody blocking FcγRIIB

Thu, Jun 4, 2026 9:50AM–11:20AM

III-034Neelima Patnaikuni

AN IN-SILICO APPROACH TO SUPPORT THE ANTIBODY DRUG CONJUGATE (ADC) COMBINATIONS TRIAL DESIGN: IMPACT OF PROPHYLACTIC RESCUE ON EFFICACY

Thu, Jun 4, 2026 9:50AM–11:20AM

III-035Elsa Hélène Smith

Limited pharmacokinetic and pharmacodynamic modelling research of
lymphodepleting agents in CAR-T cell therapy: a literature review

Thu, Jun 4, 2026 9:50AM–11:20AM

III-036Huybrecht T'jollyn

MODEL-INFORMED DRUG DEVELOPMENT TO SUPPORT DOSE SELECTION OF PASRITAMIG, A KLK2×CD3 BISPECIFIC ANTIBODY, IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Thu, Jun 4, 2026 9:50AM–11:20AM

III-037Alina Volkova

A Model-Informed Quantitative Framework for First-in-Human Dose Selection of T-Cell Receptor Mimetics in Acute Myeloid Leukemia

Thu, Jun 4, 2026 9:50AM–11:20AM

III-038Sybrand Zielhuis

The relationship between pre-operative ipilimumab and nivolumab pharmacokinetics and treatment outcome in locoregionally advanced urothelial cancer

Thu, Jun 4, 2026 9:50AM–11:20AM

III-039Magnus Åstrand

Opemalirsen antisense oligonucleotide targeting the APOL1 mRNA provide dose-dependent APOL1 reduction in plasma

Thu, Jun 4, 2026 9:50AM–11:20AM

III-040Núria Buil-Bruna

From mechanistic insight to parsimonious models: Modelling IL-18 and aletekitug to inform target engagement

Thu, Jun 4, 2026 9:50AM–11:20AM

III-041Gerbert Coen De Waard

Modelling SARS-CoV-2-specific antibody responses to personalize vaccination strategies as a tool for pandemic preparedness

Thu, Jun 4, 2026 9:50AM–11:20AM

III-042Janice Jia Ni Goh

Developing semi-mechanistic population pharmacokinetic models to assess clinical impact of known and novel pharmacogenomic CYP2D6 variants in a diverse Asian population

Thu, Jun 4, 2026 9:50AM–11:20AM

III-043Itziar Irurzun-Arana

PHARMACOKINETIC (PK) AND PHARMACODYNAMIC (PD) MODELING OF GALNAC-SIRNA GSK4532990 HSD17B13 KNOCKDOWN: INFORMING SKYLINE PHASE 2 PRIMARY ENDPOINTS AND OPTIMAL DOSING IN MASH

Thu, Jun 4, 2026 9:50AM–11:20AM

III-044Christos Kaikousidis

Using DeepNLME to identify promising biomarkers with an application to disease progression modelling of Alzheimer’s disease

Thu, Jun 4, 2026 9:50AM–11:20AM

III-045Mathilde Lacroix

DIALYSATE-GUIDED MODEL-INFORMED PRECISION DOSING OF MEROPENEM DURING CRRT

Thu, Jun 4, 2026 9:50AM–11:20AM

III-046Anna Lundahl

popPKPD modeling of AZD7798-mediated depletion of CCR9+ T cells in healthy volunteers

Thu, Jun 4, 2026 9:50AM–11:20AM

III-047Shota Muraki

A QSP Model to Describe the Time Course of Tolvaptan’s Diuretic Effect in Heart Failure Patients with Fluid Overload

Thu, Jun 4, 2026 9:50AM–11:20AM

III-048Alejandro Perez Pitarch

PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION TO CHARACTERIZE PATIENTS WHO MAY BENEFIT FROM MONTHLY DOSING WITH AFLIBERCEPT 8 MG

Thu, Jun 4, 2026 9:50AM–11:20AM

III-049Sylvie Retout

Pharmacokinetic/Pharmacodynamic and Disease Progression Models to support Sefaxersen Phase 2 read out in Patients with Geographic Atrophy

Thu, Jun 4, 2026 9:50AM–11:20AM

III-050Maja Skataric

INTEGRATED POPULATION PHARMACOKINETIC AND EXPOSURE-RESPONSE MODELING OF ENLICITIDE IN HYPERCHOLESTEROLEMIA PATIENTS SUPPORTS CLINICAL DOSE RECOMMENDATION ACROSS PATIENT SUBGROUPS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-051Charlotte Thomas

Comparative Quantification of Antibiotic Interactions Using Point Estimates, Response‑Surface Models, and Mechanistic Approaches

Thu, Jun 4, 2026 9:50AM–11:20AM

III-052Sergei Vavilov

Integrin α4β7 pathway in the QSP model of IBD describes vedolizumab efficacy

Thu, Jun 4, 2026 9:50AM–11:20AM

III-053Luong Vuong

OPTIMISING POSACONAZOLE DOSING IN CHILDREN THROUGH POPULATION PHARMACOKINETIC MODELLING AND SIMULATION

Thu, Jun 4, 2026 9:50AM–11:20AM

III-054Heejae Won

POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING AND SIMULATION ANALYSIS OF LESIGERCEPT, A LONG-ACTING IgETrap-Fc PROTEIN, TO SUPPORT DOSE SELECTION IN PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA

Thu, Jun 4, 2026 9:50AM–11:20AM

III-055Joe Standing

Mechanistic Modelling of SARS-CoV-2 Viral Dynamics and Antiviral Effects to Link Viral Exposure with Clinical Outcomes

Thu, Jun 4, 2026 9:50AM–11:20AM

III-056Mélanie Karlsen

Comparison of an uncertainty-based dynamical SCM-ML approach with classical covariate model building techniques

Thu, Jun 4, 2026 9:50AM–11:20AM

III-057Aziz Ouerdani

SEEING THE FOREST FOR THE TREES: FOREST PLOTS IN PHARMACOMETRICS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-058Celine Brochot

Applying Sampling Importance Resampling to Improve Simcyp PBPK Models Predictions Performance

Thu, Jun 4, 2026 9:50AM–11:20AM

III-059Daichi Yamaguchi

Development of averaged population pharmacokinetic model of vancomycin for paediatric patients using Bayesian model averaging approach

Thu, Jun 4, 2026 9:50AM–11:20AM

III-060James Craig

Quantitative Predictive Check (QPC): A Scalar Framework for Objective and Optimization-Ready VPC Evaluation

Thu, Jun 4, 2026 9:50AM–11:20AM

III-061Kevin Mcnally

Sensitivity analysis and calibration for a computationally expensive PBPK model: a case study for the
PERSERIS™ in-situ forming PLGA-based implant

Thu, Jun 4, 2026 9:50AM–11:20AM

III-062Nikolaos Alimpertis

Finite Pharmacokinetics (FTPK) Software: A Giant Step Toward Model-Informed Drug and Generics Development (MIDGD)

Thu, Jun 4, 2026 9:50AM–11:20AM

III-063Hyojin Cho

Physiologically Based Pharmacokinetic Modeling to Evaluate Drug–Herbal Interactions Between Conventional GERD Therapies and Banhasasim-tang

Thu, Jun 4, 2026 9:50AM–11:20AM

III-064Wilbert de Witte

Validation and refinement of the large molecule biodistribution model in PK-Sim.

Thu, Jun 4, 2026 9:50AM–11:20AM

III-065Mgambi Gideon Gamba

UNDERSTANDING THE ORAL BIOAVAILABILITY OF VORICONAZOLE: A STEP TOWARDS A COMPREHENSIVE CYP2C19‑ AND CYP3A4‑MEDIATED DRUG‑DRUG‑GENE INTERACTION NETWORK

Thu, Jun 4, 2026 9:50AM–11:20AM

III-066Zhilan Huang

IMPACT OF CYP3A4 ONTOGENY ON PREDICTION OF DRUG CLEARANCE IN YOUNG PAEDIATRIC PATIENTS USING PHYSIOLOGICALLY BASED PHARMACOKINETIC (PBPK) MODELING

Thu, Jun 4, 2026 9:50AM–11:20AM

III-067Jonas Langeraert

VALIDATION OF THE ACATPLUS MECHANISTIC COLONIC ABSORPTION MODEL IN GASTROPLUS USING A GUT-TARGETED COMPOUND

Thu, Jun 4, 2026 9:50AM–11:20AM

III-068Paulette Magnas

PHYSIOLOGICALLY BASED PHARMACOKINETIC MODELING OF ELEXACAFTOR–TEZACAFTOR–IVACAFTOR DURING PREGNANCY WITH INTEGRATED EX VIVO HUMAN PLACENTAL TRANSFER DATA TO PREDICT MATERNAL AND FETAL EXPOSURE

Thu, Jun 4, 2026 9:50AM–11:20AM

III-069Adrien Olama

A FIT-FOR-PURPOSE PHYSIOLOGICALLY BASED PHARMACOKINETIC APPROACH FOR INTRANASAL ANALGESICS: APPLICATION TO KETAMINE AND FENTANYL ANALOGS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-070Priya Sharma

DISEASE-INFORMED PBPK MODELLING OF RIFAMPICIN: MECHANISTIC INTEGRATION OF BILE SALT–MEDIATED DISSOLUTION TO PREDICT PHARMACOKINETIC VARIABILITY IN HEPATOBILIARY CONDITIONS

Thu, Jun 4, 2026 09:50AM–11:20AM

III-071Severine Urdy

DEVELOPMENT OF A PHYSIOLOGICALLY BASED PHARMACOKINETIC MODEL OF AN ANTI-HER2 ANTIBODY-DRUG CONJUGUATE WITH REZETECAN PAYLOAD IN MICE

Thu, Jun 4, 2026 9:50AM–11:20AM

III-072Shuying Yang

MODEL-INFORMED DRUG DEVELOPMENT FOR IBREXAFUNGERP IN ACUTE VULVOVAGINAL CANDIDIASIS: APPLICATION OF PBPK AND EXPOSURE–RESPONSE MODELING TO SUPPORT DRUG SUBSTANCE MANUFACTURING CHANGES

Thu, Jun 4, 2026 9:50AM–11:20AM

III-073Srishti Nagaraj

MODELLING DOSE-RESPONSE AND PATIENT ENROLMENT ACROSS MULTIPLE IVF TREATMENT CYCLES OF FOLLITROPIN DELTA

Thu, Jun 4, 2026 9:50AM–11:20AM

III-074Stefan Wetzel

Biomarker-Guided Dose Selection Facilitated by a
C-Peptide Model in Type 1 Diabetes Patients

Thu, Jun 4, 2026 9:50AM–11:20AM

III-075Francesco Bellanti

Pharmacometric Analysis of Givinostat to Support Individualized Dosing Recommendations in Pediatric Patients with Duchenne Muscular Dystrophy

Thu, Jun 4, 2026 9:50AM–11:20AM

III-076Nele Goeyvaerts

Population Pharmacokinetic and Pharmacodynamic Modeling of Canagliflozin in Paediatric Patients with Type 2 Diabetes Mellitus

Thu, Jun 4, 2026 9:50AM–11:20AM

III-077Sonoko Kawakatsu

Population pharmacokinetic (popPK) analysis of tenofovir alafenamide (TAF) and tenofovir (TFV) in children with HIV-1 ≥1 month of age

Thu, Jun 4, 2026 9:50AM–11:20AM

III-078Najia Rahim

Physiologically Based Pharmacokinetic Modeling of Cefotaxime to Inform Pediatric Dosing in Renal Impairment

Thu, Jun 4, 2026 9:50AM–11:20AM

III-079Mohammed Rohi Sanoufi

Population pharmacokinetics of intravenous Ceftazidime in critically ill paediatric patients

Thu, Jun 4, 2026 9:50AM–11:20AM

III-080Maria Xiberras

Pharmacodynamics of morphine and paracetamol for analgesia after paediatric cardiac surgery: A repeated time-to-event analysis

Thu, Jun 4, 2026 9:50AM–11:20AM

III-081A. Yin Edwards

CONCENTRATION-QTC ANALYSIS OF TOVORAFENIB IN PATIENTS WITH RAF-ALTERED, RELAPSED/REFRACTORY PEDIATRIC LOW-GRADE GLIOMA, ADVANCED SOLID TUMORS AND MELANOMA

Thu, Jun 4, 2026 9:50AM–11:20AM

III-082Joanna Parkinson

Opemalirsen antisense oligonucleotide targeting the APOL1 mRNA does not prolong the QTc interval.

Thu, Jun 4, 2026 9:50AM–11:20AM

III-083Diego Vera-Yunca

Safety Analysis of SAB-142, a Fully Human Anti-Thymocyte Globulin, Demonstrates Immunomodulatory Effects on Lymphocytes

Thu, Jun 4, 2026 9:50AM–11:20AM

III-084Ali Farnoud

An Interactive Shiny Application for Machine Learning-Driven Covariate Selection in Pharmacometrics

Thu, Jun 4, 2026 9:50AM–11:20AM

III-085Manuel Huth

NoLimits.jl: A flexible Julia framework for nonlinear, neural and latent-state mixed-effects modeling

Thu, Jun 4, 2026 9:50AM–11:20AM

III-086Minji Kwon

Prediction of Myotoxicity, Nephrotoxicity, and Hepatotoxicity Among Patients Receiving Lipid-Lowering Agents: A FAERS-Based Pharmacovigilance Study

Thu, Jun 4, 2026 9:50AM–11:20AM

III-087Alina Melnikova

Efficient generation of virtual populations using machine learning in R

Thu, Jun 4, 2026 9:50AM–11:20AM

III-088Lucas Pereira

MULTIDIMENSIONAL SCALING FOR LONGITUDINAL DATA EMBEDDINGS IN PHARMACOMETRICS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-089Dennis Reddyhoff

ACTIVE LEARNING WITH BAYESIAN OPTIMIZATION FOR EFFICIENT VIRTUAL POPULATION GENERATION USING QUANTITATIVE SYSTEMS PHARMACOLOGY MODELS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-090Martin Soucail

Automating Tumor Dynamics model discovery with Large Language Models

Thu, Jun 4, 2026 9:50AM–11:20AM

III-091Massinissa Beldjenna

Modeling the stochasticity of bacterial resistance emergence to bacteriophages

Thu, Jun 4, 2026 9:50AM–11:20AM

III-092Jeroen Elassaiss-schaap

A population covariate modeling framework for IMPRES-M, the impulse-response modeling for population PK analysis based on P-splines

Thu, Jun 4, 2026 9:50AM–11:20AM

III-093E. Niclas Jonsson

A STRUCTURED APPROACH TO PHARMACOMETRIC COVARIATE MODELING: WHY THE ESTIMAND IS THE FIRST DECISION AND THE METHOD THE SECOND

Thu, Jun 4, 2026 9:50AM–11:20AM

III-094Mihaly Leiwolf

Model Ensembling and Machine Learning Approaches to Predict the First Dose of Amoxicillin in Intensive Care

Thu, Jun 4, 2026 9:50AM–11:20AM

III-095Ben Miles

A semi-mechanistic intranasal PBPK framework implemented in MoBi

Thu, Jun 4, 2026 9:50AM–11:20AM

III-096Antoine Pitoy

Generating Realistic Virtual Populations for In Silico Clinical Trials to Inform Phase 3 Trial Design: Application to Isatuximab in Relapsed Refractory Multiple Myeloma

Thu, Jun 4, 2026 9:50AM–11:20AM

III-097Johannes Schropp

Using Generative AI Variational Autoencoders with Neural Ordinary Differential Equations to Improve Nonlinear Mixed-Effects Pharmacometric Modeling

Thu, Jun 4, 2026 9:50AM–11:20AM

III-098Hidde van de Beek

Treating models as data: advancing model-based meta-analysis through aggregate data modelling

Thu, Jun 4, 2026 9:50AM–11:20AM

III-099Huixin Yu

BEYOND EMPIRICAL BIOAVAILABILITY SCALING: A MECHANISTIC MODEL INCORPORATING PRE- AND POST-SYSTEMIC SATURABLE PROCESSES TO CHARACTERIZE NON-LINEAR PK OF ORALLY ADMINISTERED SMALL MOLECULES

Thu, Jun 4, 2026 9:50AM–11:20AM

III-100Happy Djokoto

QUANTIFYING THE IMPACT OF LLOQ AND ULOQ CENSORING ON M3 ESTIMATION PERFORMANCE IN NONMEM

Thu, Jun 4, 2026 9:50AM–11:20AM

III-101Anna Mikhailova

R-based Bayesian workflow for ODE pharmacometrics modeling: generalized dapagliflozin PK model as a case study

Thu, Jun 4, 2026 9:50AM–11:20AM

III-102Arno Strouwen

InVitroInVivoCorrelation.jl: A MODULAR JULIA PACKAGE FOR LEVEL A IVIVC

Thu, Jun 4, 2026 9:50AM–11:20AM

III-103Igor Vasyutin

The Decision-Equivalence Metric (DEM) Method Based Evaluation of Biomarker Surrogacy in MASH

Thu, Jun 4, 2026 9:50AM–11:20AM

III-104Koichiro Yoneyama

COUNTING THE BIOCHEMICAL REACTION OCCURRENCES: A STATISTICAL IMPLICATION OF THE FIRST-ORDER RATE CONSTANTS IN KINETIC MODELS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-105Mehdi El Hassani

MAKING SPARSE DATA INFORMATIVE: POPULATION PHARMACOKINETICS AND D-OPTIMAL DESIGN FOR ORAL CIPROFLOXACIN IN ADULTS ≥75 YEARS

Thu, Jun 4, 2026 9:50AM–11:20AM

III-106Ziheng Hu

Model-Informed Design of Interim Analysis for a PK Bridging Study and Optimization of Its Operating Characteristics

Thu, Jun 4, 2026 9:50AM–11:20AM

III-107Veshni Pillay-fuentes Lorente

OPTIMISING SAMPLING DESIGN TO ENHANCE PHARMACOKINETIC EVALUATION OF COLISTIN IN NEONATES

Thu, Jun 4, 2026 9:50AM–11:20AM

III-108Pyry Valitalo

Paediatric pharmacokinetic studies could be optimized for the precision of the clinically relevant exposure endpoint instead of PK parameter precision

Thu, Jun 4, 2026 9:50AM–11:20AM